Risk stratification of childhood medulloblastoma in the molecular era: the current consensus

HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma

(2016) Yanxin Pei et al.   CANCER CELL

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

(2016) Eric M Thompson et al.   LANCET ONCOLOGY

Divergent clonal selection dominates medulloblastoma at recurrence

(2016) A. Sorana Morrissy et al.   NATURE

Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease

(2015) Rebecca M. Hill et al.   CANCER CELL

Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy

(2015) Hugo Câmara-Costa et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032

(2015) Giles W. Robinson et al.   JOURNAL OF CLINICAL ONCOLOGY

Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?

(2015) Vijay Ramaswamy et al.   NEURO-ONCOLOGY

Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours

(2015) Tobias Goschzik et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

p53 and Medulloblastoma

(2015) Vijay Ramaswamy et al.   Cold Spring Harbor Perspectives in Medicine

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma

(2015) Jonas Ecker et al.   Acta Neuropathologica Communications

Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort

(2014) Torsten Pietsch et al.   ACTA NEUROPATHOLOGICA

Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition

(2014) Marcel Kool et al.   CANCER CELL

Cytogenetic Prognostication Within Medulloblastoma Subgroups

(2014) David J.H. Shih et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Craniospinal Dose, Boost Volume, and Neurologic Complications on Intellectual Outcome in Patients With Medulloblastoma

(2014) Iska Moxon-Emre et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma

(2014) Paul A. Northcott et al.   NATURE

WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma

(2014) Nataliya Zhukova et al.   Acta Neuropathologica Communications

Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group

(2013) Nicholas G. Gottardo et al.   ACTA NEUROPATHOLOGICA

DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies

(2013) Edward C. Schwalbe et al.   ACTA NEUROPATHOLOGICA

BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

(2013) P. Bandopadhayay et al.   CLINICAL CANCER RESEARCH

Quality of Survival and Growth in Children and Young Adults in the PNET4 European Controlled Trial of Hyperfractionated Versus Conventional Radiation Therapy for Standard-Risk Medulloblastoma

(2013) Colin Kennedy et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Subgroup-Specific Prognostic Implications ofTP53Mutation in Medulloblastoma

(2013) Nataliya Zhukova et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Risk Medulloblastoma: A Pediatric Oncology Group Randomized Trial of Chemotherapy Before or After Radiation Therapy (POG 9031)

(2013) Nancy J. Tarbell et al.   JOURNAL OF CLINICAL ONCOLOGY

Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis

(2013) Vijay Ramaswamy et al.   LANCET ONCOLOGY

Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas

(2013) Ratika Kunder et al.   NEURO-ONCOLOGY

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

(2012) Marcel Kool et al.   ACTA NEUROPATHOLOGICA

Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial

(2012) Birgitta Lannering et al.   JOURNAL OF CLINICAL ONCOLOGY

HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment

(2012) Till Milde et al.   JOURNAL OF NEURO-ONCOLOGY

Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations

(2012) Trevor J. Pugh et al.   NATURE

Novel mutations target distinct subgroups of medulloblastoma

(2012) Giles Robinson et al.   NATURE

Dissecting the genomic complexity underlying medulloblastoma

(2012) David T. W. Jones et al.   NATURE

Clonal selection drives genetic divergence of metastatic medulloblastoma

(2012) Xiaochong Wu et al.   NATURE

Subgroup-specific structural variation across 1,000 medulloblastoma genomes

(2012) Paul A. Northcott et al.   NATURE

Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961

(2012) Roger J. Packer et al.   NEURO-ONCOLOGY

Radiation therapy quality in CCG/POG intergroup 9961: implications for craniospinal irradiation and the posterior fossa boost in future medulloblastoma trials

(2012) Bernadine Donahue et al.   Frontiers in Oncology

Biological and clinical heterogeneity of MYCN-amplified medulloblastoma

(2011) Andrey Korshunov et al.   ACTA NEUROPATHOLOGICA

Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups

(2011) David W. Ellison et al.   ACTA NEUROPATHOLOGICA

Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples

(2011) Paul A. Northcott et al.   ACTA NEUROPATHOLOGICA

Molecular subgroups of medulloblastoma: the current consensus

(2011) Michael D. Taylor et al.   ACTA NEUROPATHOLOGICA

Predicting Relapse in Patients With Medulloblastoma by Integrating Evidence From Clinical and Genomic Features

(2011) Pablo Tamayo et al.   JOURNAL OF CLINICAL ONCOLOGY

Adult Medulloblastoma Comprises Three Major Molecular Variants

(2011) Marc Remke et al.   JOURNAL OF CLINICAL ONCOLOGY

FSTL5Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma

(2011) Marc Remke et al.   JOURNAL OF CLINICAL ONCOLOGY

Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study

(2011) Anita Villani et al.   LANCET ONCOLOGY

Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome

(2010) Yoon-Jae Cho et al.   JOURNAL OF CLINICAL ONCOLOGY

Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables

(2010) David W. Ellison et al.   JOURNAL OF CLINICAL ONCOLOGY

Medulloblastoma Comprises Four Distinct Molecular Variants

(2010) Paul A. Northcott et al.   JOURNAL OF CLINICAL ONCOLOGY

Medulloblastoma Variants: Age-Dependent Occurrence and Relation to Gorlin Syndrome--A New Clinical Perspective

(2009) M. L. Garre et al.   CLINICAL CANCER RESEARCH

Hyperfractionated Accelerated Radiotherapy in the Milan Strategy for Metastatic Medulloblastoma

(2008) Lorenza Gandola et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features

(2008) Marcel Kool et al.   PLoS One